Kahn Swick & Foti LLC continues its investigation into the officers and directors of Humana Inc., focusing on whether they breached their fiduciary duties to shareholders or violated state or federal laws. The law firm's scrutiny follows a series of financial disclosures in early 2024 that revealed rising medical costs and missed earnings targets, leading to a securities class action lawsuit that has been allowed to proceed.

On January 18, 2024, Humana announced its financial results for the fourth quarter and full year 2023. The company reported that its benefits expense ratio increased to approximately 91.4% for the fourth quarter of 2023 and approximately 88% for the full year 2023. This resulted in 2023 adjusted earnings per share (EPS) of $26.09, which was more than $2 per share less than the company had predicted in November 2023.

Subsequently, on January 25, 2024, Humana disclosed a loss for the fourth quarter of 2023. The company indicated that higher medical costs would persist throughout 2024, projecting adjusted EPS of only $16 per share for the year. This forecast represented a $10 per share decrease from 2023 and fell well below analysts' expectations of $29 per share.

Following these disclosures, Humana and certain executives were named in a securities class action lawsuit. The complaint alleges that the defendants failed to disclose material information during the Class Period, violating federal securities laws. Recently, the court presiding over the case denied the company's motion to dismiss in part, allowing the lawsuit to move forward.

Key Financial Disclosures

Kahn Swick & Foti LLC, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is a boutique securities litigation firm. The firm is seeking information from long-term holders of Humana shares to assist in its investigation regarding potential corporate malfeasance.

Evercore ISI Group analyst Elizabeth Suzuki has maintained an In-Line rating on Humana while raising the price target to $370 from $250. The new target indicates a revised valuation outlook for the healthcare company's stock.

The rating action follows a review of Humana's market position and financial prospects. Despite the higher price target, the In-Line stance suggests the stock is expected to perform in line with the broader market averages.

Humana operates in the healthcare sector, and the adjusted target reflects updated projections regarding its business performance. The analyst's report provides guidance for investors monitoring the company's stock movements.